Search research articles
Contact Us
Filters
Showing results (1-10 of 10) with videos related to
Page
of 1
Sort By:
Expert Opinion on Investigational Drugs
|
March 19, 2011
Pomalidomide therapy for myeloma
Stephen Schey, Karthik Ramasamy
International Journal of Endocrinology and Metabolism
|
July 16, 2013
A Novel Medical Treatment of Cushing's Due to Ectopic ACTH in a Patient With Neurofibromatosis Type 1
Gul Bano, Farheen Mir, Nigel Beharry, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
May 18, 2011
Alemtuzumab-based reduced-intensity conditioning allogeneic transplantation for myeloma and plasma cell leukemia - a single-institution experience
Karthik Ramasamy, Shameem Mahmood, Ziyi Lim, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
July 8, 2015
Pomalidomide and Low-Dose Dexamethasone Improves Health-Related Quality of Life and Prolongs Time to Worsening in Relapsed/Refractory Patients With Multiple Myeloma Enrolled in the MM-003 Randomized Phase III Trial
Katja Weisel, Meletios Dimopoulos, Kevin W Song, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 28, 2002
Role of nonmyeloablative allogeneic stem-cell transplantation after failure of autologous transplantation in patients with lymphoproliferative malignancies
Katharine Branson, Rajesh Chopra, Panagiotis D Kottaridis, et al.
Blood
|
October 18, 2002
Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders
José A Pérez-Simón, Panagiotis D Kottaridis, Rodrigo Martino, et al.
The Lancet. Oncology
|
September 7, 2013
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial
Jesus San Miguel, Katja Weisel, Philippe Moreau, et al.
Blood Advances
|
December 7, 2020
International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease
Frits van Rhee, Eric Oksenhendler, Gordan Srkalovic, et al.
Blood
|
September 6, 2018
RNA-seq of newly diagnosed patients in the PADIMAC study leads to a bortezomib/lenalidomide decision signature
Michael A Chapman, Jonathan Sive, John Ambrose, et al.
Blood
|
September 6, 2018
International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease
Frits van Rhee, Peter Voorhees, Angela Dispenzieri, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 10) with videos related to
Sort By:
Page
of 1
Expert Opinion on Investigational Drugs
|
March 19, 2011
Pomalidomide therapy for myeloma
Stephen Schey, Karthik Ramasamy
International Journal of Endocrinology and Metabolism
|
July 16, 2013
A Novel Medical Treatment of Cushing's Due to Ectopic ACTH in a Patient With Neurofibromatosis Type 1
Gul Bano, Farheen Mir, Nigel Beharry, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
May 18, 2011
Alemtuzumab-based reduced-intensity conditioning allogeneic transplantation for myeloma and plasma cell leukemia - a single-institution experience
Karthik Ramasamy, Shameem Mahmood, Ziyi Lim, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
July 8, 2015
Pomalidomide and Low-Dose Dexamethasone Improves Health-Related Quality of Life and Prolongs Time to Worsening in Relapsed/Refractory Patients With Multiple Myeloma Enrolled in the MM-003 Randomized Phase III Trial
Katja Weisel, Meletios Dimopoulos, Kevin W Song, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 28, 2002
Role of nonmyeloablative allogeneic stem-cell transplantation after failure of autologous transplantation in patients with lymphoproliferative malignancies
Katharine Branson, Rajesh Chopra, Panagiotis D Kottaridis, et al.
Blood
|
October 18, 2002
Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders
José A Pérez-Simón, Panagiotis D Kottaridis, Rodrigo Martino, et al.
The Lancet. Oncology
|
September 7, 2013
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial
Jesus San Miguel, Katja Weisel, Philippe Moreau, et al.
Blood Advances
|
December 7, 2020
International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease
Frits van Rhee, Eric Oksenhendler, Gordan Srkalovic, et al.
Blood
|
September 6, 2018
RNA-seq of newly diagnosed patients in the PADIMAC study leads to a bortezomib/lenalidomide decision signature
Michael A Chapman, Jonathan Sive, John Ambrose, et al.
Blood
|
September 6, 2018
International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease
Frits van Rhee, Peter Voorhees, Angela Dispenzieri, et al.
Page
of 1